5 Nov 2026My final shortlistBest results to investigate first Stock My classification Reason CENTUM Strong Buy candidat...

Write here new

Visibility: public

Added: 2026-11-05 06:30:49 | Edited: 2026-11-05 07:05:36

5 Nov 2026

My final shortlist

Best results to investigate first

Stock	My classification	Reason
CENTUM	Strong Buy candidate	Strong growth in revenue, EBITDA and profit
SCI	Strong Buy candidate	Very strong operating improvement
JAYAGROGN	Strong Buy candidate	Strong growth across all three measures TRAP 100 PAN CARD
SANATHAN	Strong Buy candidate	Exceptional revenue and profit growth
SOMANYCERA	Buy candidate	Strong margin expansion and profit growth NO WARNING from ZERODHA so GOOD

Avoid / investigate before buying

Stock	My classification	Reason
PIIND	Strong Sell signal	Major deterioration in profitability; verify revenue data
MAFATIND	Strong Sell signal	Revenue, EBITDA and profit all declined INTRADAY is BLOCKED
ESABINDIA	Sell	Profit and margin deterioration
PLATIND	Sell	Revenue growth not translating into profit
MAXESTATES	Sell / Wait	EBITDA and profit declined despite revenue growth

STOCKS TO WATCH: LENSKART, NYKAA, APOLLOTYRE, DABUR, KIRLOSENG, CHALET, SOMANYCERA, PWL, APOLLOHOSP, PREMIERENE, MAYURUNIQ, NHPC, UNIPARTS, PIIND, SCI, AUROPHARMA, ENTERO, GALAXYSURF, VINDHYATEL, MAXESTATES, CENTUM

Detailed verdict table

Result-based assessment • Q2 FY27 • Not a valuation-based price target

Stock	Result assessment	Verdict	My analysis
LENSKART	Excellent	BUY	Revenue +32.5%, PAT +106%. Strong growth and improving margins. Valuation is the main risk. Investor Presentation · Indian Stock Alerts+1
NYKAA	Excellent	BUY	Revenue +28%, PAT +207%; fashion business moving into profitability. Strong operating improvement. Investor Presentation · Indian Stock Alerts+1
APOLLOTYRE	Mixed	HOLD / AVOID FRESH BUY	Revenue and profit increased, but EBITDA margin fell sharply from 14.94% to 10.74%.
DABUR	Positive	ACCUMULATE	Revenue +11.6%, PAT +12.1%. Stable consumer business, but growth is moderate. moizz
KIRLOSENG	Weak	SELL / AVOID	Revenue grew, but EBITDA, margin and profit declined. Operating performance is deteriorating.
CHALET	Mixed	HOLD	Revenue declined around 32%, while profit rose around 40%. Needs investigation into the source of profit improvement. moizz
SOMANYCERA	Excellent	BUY	Revenue +25.6%, PAT +237.6%. EBITDA and margin improved significantly. moizz
PWL	Positive	BUY / ACCUMULATE	Revenue +18.2%, PAT +106%. Good earnings growth; monitor cash flow and education-business economics. moizz
APOLLOHOSP	Excellent	BUY	Revenue, EBITDA and profit all increased strongly. Healthcare demand supports the growth outlook.
PREMIERENE	Positive	ACCUMULATE	Revenue and profit increased substantially, but EBITDA margin declined. Growth is strong, though margin quality needs monitoring.
MAYURUNIQ	Positive	BUY	Revenue +6%, EBITDA +17%, profit +7% approximately. Margin improvement is encouraging; growth is not particularly fast.
NHPC	Excellent	BUY / ACCUMULATE	Revenue and profit grew strongly. However, project execution and capital expenditure remain important risks. NHPC+1
UNIPARTS	Positive	BUY	Revenue +36.7%, PAT +38.2%. EBITDA and margins also improved. Good earnings momentum. moizz
PIIND	Very weak	AVOID / SELL	EBITDA and profit dropped sharply; margin nearly halved. Revenue figure in the feed appears inconsistent, so verify the official filing before acting.
SCI	Excellent	STRONG BUY CANDIDATE	Revenue increased from ₹1,339 Cr to ₹2,291 Cr; PAT from ₹189 Cr to ₹578 Cr. Excellent earnings improvement, but shipping is cyclical. Cruxal
AUROPHARMA	Excellent	BUY	Revenue +23.9%, PAT +32.5%. EBITDA and margins improved. Strong pharmaceutical performance. moizz
ENTERO	Positive	BUY / ACCUMULATE	Revenue +33%, EBITDA improved substantially and profit increased. Watch its relatively thin operating margin. Cruxal
GALAXYSURF	Positive	BUY	Revenue +36%, EBITDA +73% approximately, with improved margins and profit. Good operating momentum. Cruxal
VINDHYATEL	Mixed	HOLD	Revenue declined, but EBITDA and profit improved. Better margins are encouraging, but revenue weakness needs monitoring. Cruxal
MAXESTATES	Weak	AVOID FRESH BUY	Revenue rose slightly, but EBITDA and profit declined significantly; margin compressed sharply.
CENTUM	Excellent	STRONG BUY CANDIDATE	Revenue +57%, EBITDA nearly doubled and profit rose substantially. Strong improvement in operating margin.

My final ranking

These are rankings by earnings quality and growth, not by expected share-price return.

Priority	Stock	Verdict
1	CENTUM	Strong Buy candidate
2	SCI	Strong Buy candidate
3	LENSKART	Buy
4	SOMANYCERA	Buy
5	AUROPHARMA	Buy
6	APOLLOHOSP	Buy
7	GALAXYSURF	Buy
8	NYKAA	Buy
9	UNIPARTS	Buy
10	ENTERO	Buy / Accumulate
11	PWL	Buy / Accumulate
12	NHPC	Buy / Accumulate
13	PREMIERENE	Accumulate
14	MAYURUNIQ	Buy
15	DABUR	Accumulate
16	CHALET	Hold
17	VINDHYATEL	Hold
18	APOLLOTYRE	Hold / Avoid fresh buy
19	MAXESTATES	Avoid fresh buy
20	KIRLOSENG	Sell / Avoid
21	PIIND	Avoid / Sell